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BACKGROUND: Tumour cells may persist at the operative site after seemingly adequate surgery. Radiotherapy is often given in an
attempt to prevent repopulation, but this modality cannot be relied upon to prevent locoregional recurrence. An alternative strategy
is to take advantage of the requirement of tumour cells to develop an independent blood supply and block this process to prevent
recurrence.
METHODS: In this study, we evaluate the effect of the angiogenesis inhibitor, ZD4190, using a rodent model of residual carcinoma in
deep tissues, mimicking the clinical scenario where low numbers of malignant cells persist at the operative site.
RESULTS: The tumour burden that could be eliminated was dependent on the site where the cells were implanted. Immediate
treatment with ZD4190 prevented outgrowth of up to 2.5 10
5 cells in the rectus muscle and 1 10
5 in the gastrocnemius,
whereas control animals developed large tumours. When more than 2.5 10
6 cells were implanted into the rectus or 1 10
6 into
the gastrocnemius and treatment was maintained for 3 weeks, the carcinomas that developed in ZD4190-treated animals showed a
reduced microvessel density and increased necrosis when compared with the vehicle-treated controls, but an infiltrative growth
pattern was common.
CONCLUSION: These findings suggest that antiangiogenic agents have a role to play in preventing outgrowth of residual carcinoma and
are likely to be most effective when the tumour burden is minimal.
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The high rate of recurrence after seemingly adequate surgery and
radiotherapy for tumours arising in the head neck area implies the
presence of residual disease. Studies using molecular diagnostics,
based on finding the same p53 mutation in a carcinoma and the
surrounding normal tissues, have confirmed the presence of
malignant cells in tissues assessed as being tumour free by the
pathologist (Brennan et al, 1995; Partridge et al, 2000; van Houten
et al, 2002, 2004). Most effort has been focused on detection of
residual carcinoma at the operative site as locoregional recurrence,
rather than distant metastasis, is the most important cause of
treatment failure for these cases (Partridge et al, 2005).
The samples that are forwarded for this ultrasensitive analysis are
referred to as ‘molecular margins’. This is important as the term
surgical margins frequently causes confusion, as it may be wrongly
assumed that the tissues examined are taken from the edge of the
resected carcinoma, rather than from the normal tissues. Analysis of
both mucosal and deep ‘molecular margins’ has revealed that the
finding of p53 mutations in deep margins is more strongly associated
with development of local recurrence than p53-mutation-positive
mucosal margins (Huang et al,2 0 0 7 ) .As e c o n dk e yo b s e r v a t i o nt h a t
has emerged from all studies applying these new diagnostics
(Brennan et al, 1995; Partridge et al, 2000, 2005; van Houten et al,
2002, 2004; Huang et al, 2007) is that multiple tumour-positive
margins are associated with local recurrence, indicating that local
spread is more widespread than envisaged earlier. As the prognostic
significance of this residual carcinoma becomes clearer, the challenge
is to find new ways of preventing outgrowth of these remaining
malignant cells. At present, patients with close margins after surgery,
two or more tumour-positive lymph nodes or histological features
that suggest aggressive disease receive postoperative radiotherapy,
yet more than half of these cases develop locoregional recurrence.
T h ep r e s e n c eo fap53 mutation in these cancers may be relevant but
is only one of the many factors that influence the response to
radiotherapy such that new treatments need to be added to
conventional protocols if outcome is to be improved.
It is well established that tumours induce changes in the
vasculature and extracellular matrix and that malignant cells must
develop an independent blood supply to grow beyond a critical
size. In this study, we evaluated the ability of ZD4190, an orally
available inhibitor of the vascular endothelial cell growth factor
receptor 2 (VEGFR2) and of epidermal growth factor receptor
(EGFR) signalling, to block the development of vasculature
required to support outgrowth of tumour cells (Wedge et al,
2000; Ryan and Wedge, 2005). Vascular endothelial cell growth
factor plays a pivotal role in endothelial cell mitogenesis and
chemotaxis, modulating cellular–extracellular matrix interactions
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s(Wedge et al, 2000). These activities facilitate vessel sprouting and
capillary tube formation. Vascular endothelial cell growth factor
may also contribute to tumour progression through its permea-
bilising effect on the vasculature (Dvorak et al, 1995; Roberts and
Palade, 1997), and activation of VEGFR2 appears sufficient to
promote the major phenotypic responses to VEGF, including
endothelial cell proliferation, migration, survival and the induction
of vascular permeability (Wedge et al, 2002).
We used a preclinical model where defined numbers of cells are
implanted into different muscles, mimicking the clinical scenario
where residual tumour persists in deep structures postoperatively
(Oakley et al, 2002). We selected an immunocompetent host and a
cell line that forms infiltrative tumour tracts in muscle, rather than
a subcutaneous model, as most recurrence occurs in deep tissues
and the local delivery of novel therapeutics to this site is not
straightforward (Oakley et al, 2002). The cell line also carries a p53
gene mutation. This is of clinical relevance when evaluating
antiangiogenic agents as tumours lacking p53 may show reduced
apoptosis and a reduced treatment response under hypoxic
conditions (Yu et al, 2002). In pilot studies, we considered the
feasibility of developing a model of residual tumour by resecting
the greater portion of an established carcinoma. However, the
amount of residual tumour was unpredictable, whereas implanting
defined numbers of malignant cells provided a reproducible way to
examine the effects of an antiangiogenic agent at different time
points as the tumour foci developed an independent vasculature.
MATERIALS AND METHODS
Establishment of the model of minimal residual cancer
Female mice were obtained from Harlan Ltd (Oxford, UK) and
were used in accordance with institution guidelines when they
were 7–8 weeks old. Two tracts of malignant squamous
keratinocyte PDVC57B cells, which are syngeneic for C57Bl/6
mice and mimic the clinical problem by invading into muscle, were
implanted under halothane anaesthesia using a 30-gauge needle,
into each gastrocnemius muscle and five tracts were implanted
into the larger rectus muscle. This cell line carries a p53 mutation
at codon 231 (ATG-CTC) and an A–T transversion at codon 61 of
the H-ras gene (Oakley et al, 2002). A range of cells was implanted
(1–5 10
4–5 10
5 per tract), injecting as the needle was with-
drawn (Oakley et al, 2002). In some experiments, the tumour was
resected under anaesthesia, aiming to leave residual carcinoma,
and the wound closed with sutures.
Drug treatment
ZD4190 was administered by gavage suspended in 1% polysorbate
80 at 50mgkg
 1 24h after tumour cell implantation for a
maximum of 22 days. Control rodents were gavaged with the
vehicle only and a third group was untreated. In preliminary
experiments, rodents were killed on alternate days so that the
effect of ZD4190 on tumour outgrowth could be assessed and
subsequently the treatment response was evaluated at day 9 or 22.
At least five rodents were included in each treatment group.
Histopathological assessment
At appropriate time points, the animals were killed and the
tumour-bearing muscles removed for histological examination.
Tissues were fixed in zinc buffer (0.5g calcium acetate, 5g zinc
acetate, 5g zinc chloride dissolved in 1l of 0.1 M Tris, pH 7.4) for
8–12h. Each muscle was bisected at the midpoint and the two
halves embedded, with the cut surface uppermost, and processed
into wax. General tissue morphology was evaluated by the
examination of haematoxylin- and eosin-stained sections. The
combined area of the tumour tracts and any areas of necrosis were
measured using a Leica Q500IW workstation (Oakley et al, 2002).
Establishing the time point at which neoangiogenesis
occurs
To determine when proliferating endothelial cells were present in
the developing tumour tracts, pairs of rodents implanted with
tumour cells received bromodeoxyuridine (BrdU) at 40mgkg
 1
40min before killing on days 4, 6, 8, 10, 14, 16 and 18. Tissues were
processed as described above and step-serial sections examined at
100-mm intervals.
Immunohistochemistry
Pilot studies with antibodies recognising CD31, CD34, VWF and
CD105 (all BD Biosciences, Abcam, Cambridge, UK) identified rat
anti-mouse CD31, diluted 1:20 as the most appropriate reagent to
estimate the number of blood vessels present in the tumour tracts.
The secondary antibody was donkey anti-rat alkaline phosphatase
(Jackson ImmunoResearch, Stratech, Soham, UK) diluted 1:200
followed by development with the alkaline phosphatase substrate
kit (Vector Laboratories, Peterborough, UK). Sections incubated
with antibody dilutant were used as negative controls. Immuno-
localisation of VEGF was with goat anti-mouse VEGF (1:200;
Sigma, Poole, Dorset, UK), of VEGFR2 was with rabbit anti-
VEGFR2 (1:100; Zymed, Invitrogen, Paisley, UK) and of
cytokeratins with guinea pig anti-mouse (1:100; Progen, Heidel-
berg, Germany).
Step-serial sections were examined by double labelling for CD31
and BrdU. After staining for CD31, BrdU was detected with the
in situ detection kit (BD Biosciences, Oxford, UK) with
biotinylated anti-BrdU (1:10 for 1h followed by development
with streptavidin–horseradish peroxidase for 30min and visuali-
sation with DAB (3,3-diaminobenzidine; DAKO, Ely, UK)).
Proliferating endothelial cells were scored as such when they
expressed CD31 and BrdU and were associated with tubular
structures. The percentage of double-stained cells was estimated by
counting 200 nuclei. We did not find any evidence that PDVC57B
cells expressed CD31 or of cytokeratin-positive cells lining vessels
containing red blood cells, suggesting that it is unlikely that
vascular mimicry (Hendrix et al, 2000; Sood et al, 2001; Shieh et al,
2004) contributes significantly to the angiogenic response.
Determination of microvessel density following
implantation of tumour cells
Microvessels were counted within the tumour foci at the midpoint
of each muscle at days 9 and 22. At the first time point, all tumour
vessels were counted but at day 22, varying patterns of coalescing
tracts were observed and the vessels were counted for four fields at
 100 magnification, selecting one within each quadrant of the
tumour, avoiding any areas of necrosis or cystic cavities. The
counts were expressed as the mean±s.e. for an area of 80mm
2 as
this was the cross-sectional area of the smallest focus of tumour
measured at this time.
Cytotoxicity assay in monolayer culture
The cytotoxicity of ZD4190 for PDVC57B cells was established
when 10
4 cells were exposed to 1–10mM ZD4190 for 96h
before MTS solution (Promega, Southampton, UK) was added
and the optical density measured at 490nm. Cells were also
grown to 40% confluence and treated with 1–100mM ZD4190 for 7
days and the cytopathic effect examined by staining with crystal
violet.
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One-way ANOVA was used to compare the microvessel density
(MVD) and the combined area of the tumour tracts at the
midpoint of the muscles for groups of rodents treated with ZD4190
and the vehicle-treated controls. SPSS 11.1 (SPSS.com, Woking,
UK) for windows was used and a Po0.05 was considered
statistically significant.
RESULTS
Recapitulating outgrowth of residual carcinoma in deep
tissues
In pilot studies, the greater portion of an established carcinoma
was resected to mimic the clinical scenario where tumour remains
at the operative site, but the amount of residual carcinoma was
unpredictable (data not shown). In contrast, implanting defined
numbers of malignant cells provided a reproducible way to
examine the effects of an antiangiogenic agent. When 1–5 10
5
PDVC57B cells were implanted to create each tumour tract,
proliferating malignant keratinocytes were detected after 96h. The
tumour foci included fibroblasts and inflammatory cells, and by
day 7, cords of malignant cells extended between the muscle fibres
(Figure 1A). Typically, the tumour had a well-circumscribed
margin and large venules and arteries, and smaller vessels were
apparent after 16 days as well (Figure 1A). Implanting 10
4 cells to
create each tract resulted in delayed tumour outgrowth, with cords
of 2–4 layers of malignant cells being the most frequent finding.
However, rapidly growing tumour foci developed when 2–5 10
4
cells were implanted. The efficiency of tumour tract formation at
day 9, for groups of 10 rodents implanted with the same number of
cells, ranged from 76 to 95% when the results from three
consecutive experiments were assessed.
Detection of VEGF and VEGFR2 and proliferating
endothelial cells by anti-CD31 and BrdU staining
Vascular endothelial cell growth factor and VEGFR2 were detected
in clumps of PDVC57B cells and in the stroma at day 6. Following
double staining for BrdU and CD31, proliferating endothelial cells
were identified at the edge of the tumour, with vascular sprouts,
chains of endothelial cell and hyperplastic vessels detected from
day 8 (Figure 1A). Approximately 3% of the tumour endothelial
cells were positive with both markers. Similar structures were
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Figure 1 Effect of ZD4190 on tumour outgrowth in a model of residual cancer in the muscle, recapitulating the clinical scenario where malignant cells
remain in the muscle after surgery. (A) Morphology of a representative tumour tract in the rectus muscle 7 and 16 days after implantation of PDVC57B cells;
magnification:  240 (left) and  280 (right). Identification of proliferating endothelial cells by double staining for CD31 (red arrow) and BrdU (black arrow)
at the tumour periphery at day 8 and core at day 12 (magnification,  1000). (B) Gavage with ZD4190 prevented the outgrowth when up to 5 10
4
PDVC57B cells were implanted to create each tumour tract. Two representative examples of the fibrotic foci found at day 22 are shown (far left,  100)
together with a fibrotic focus with viable malignant cells (centre left,  100). In contrast, control rodents developed large tumours (centre right,  100),
as did those receiving vehicle alone although some lesions that developed in this group were associated with peripheral areas of fibrosis (far right,  100).
(C) When higher numbers of malignant cells were implanted to create each tract (41 10
5), large tumours developed in the control and vehicle-treated
groups by day 22 ( 80). The tumours present in the ZD4190-treated rodents typically showed a more infiltrative pattern of growth with cords of cells,
areas of necrosis and reduced microvascularity, as determined by CD31 staining, when compared with those that developed in the vehicle-treated group
(far right,  240).
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snumber of cells implanted did not influence the time when
proliferating endothelial cells were detected.
ZD4190 prevents outgrowth of residual tumour
When 2 10
4 PDVC57B cells were implanted to create each
tumour tract in the gastrocnemius (total of 4 10
4 cells) and
rectus (total of 1 10
5 cells) muscles, no tumours were detected
clinically for the rodents treated with ZD4190. Histological
assessment of tissues at day 22 did not reveal any evidence of
tumour in 16 of 20 muscles implanted with a total of 35 tracts, but
rather fibrotic foci with collagen fibrils, fibroblasts and scattered
inflammatory cells replaced the muscle (Figure 1B). CD31 staining
showed that many of these fibrotic foci contained large vessels, and
vascular hot spots were identified in the adjacent muscle. Four of
the tumour-bearing muscles in the test group (three rectus and one
gastrocnemius) contained fibrotic foci with central islands of
proliferating tumour as determined by BrdU staining, but these
treatment failures were confined to two rodents (Figure 1B). Viable
carcinoma cells, which were not actively proliferating, were also
detected within two fibrotic foci in the rectus (Table 1). Fibrotic
foci were also the predominant finding at sites where 5 10
4 cells
were implanted to create each tumour tract (a total of 2.5 10
5
cells for the rectus and 1 10
5 cells for the gastrocnemius) and the
rodents gavaged with ZD4190 (Table 1). Similar treatment effects
were seen when these experiments were repeated with other groups
of animals. In contrast, the tumours that developed in the control
groups were highly cellular, with darkly stained nuclei (Figure 1B)
although a proportion (10%) developing in the rectus, in the group
gavaged with the vehicle only, was associated with peripheral
fibrotic reactions that were not seen in the untreated group
(Table 1, Figure 1B).
When more than 10
5 cells were implanted to create each tract,
fibrotic foci were rarely detected and the combined area of the
tracts at the midpoint of each muscle was broadly similar
(Figure 2A) although the total number of cells implanted into
each muscle was different. The MVD of the tumours developing in
the rectus was consistently higher than that observed for the
gastrocnemius (Figure 2B), and following treatment with ZD4190,
there was a reduction in the MVD for the tumours in the
gastrocnemius at day 9 (P¼0.00, Figure 2B) but not for those in
the rectus.
By day 22, large tumours were apparent in all groups, with
clumps and cords of squamous cells admixed with loose stroma.
Many tumours had a well-circumscribed margin (Figure 1C, far
left) but others showed an infiltrative growth pattern and areas of
central necrosis. The tumours that developed in the ZD4190-
treated group were characterised by a heterogeneous growth
pattern, with dense islands of carcinoma and admixed stroma or
cord-like proliferations of malignant cells (Figure 1C). Cystic
spaces were located at the periphery in the ZD4190-treated group
(Figure 1C). At this time, the tumour area was reduced in the
rectus (Figure 2A, P¼0.004) and the fraction of the tumour
area showing necrosis was increased when ZD4190-treated
(22.32%±4.79) and vehicle-treated groups (4.93%±3.17) were
compared (P¼0.00). A similar reduction in the tumour area, and a
corresponding increase in the fraction of the tumour area showing
necrosis, was found for the gastrocnemius (21.37%±3.65 vs
4.72%±2.61, P¼0.001). A reduction in the MVD was apparent
when the ZD4190- and vehicle-treated groups were compared
(Po0.005, Figure 1C, far right, and Figure 2B) but these tumours
showed a more infiltrative growth pattern when compared with
those arising in the control group. In contrast to the inhibitory
effect of ZD4190 on tumour outgrowth in vivo, no significant
cytotoxicity was observed following exposure of PDVC57B cells to
0.1–100mM ZD4190 in vitro.








ZD4190 C V ZD4190 C V ZD4190 C V ZD4190 C V
Fibrotic foci no tumour 14 0 0 14 0 0 7 0 0 4 0 0
Fibrotic foci Brdu tumour 2 0 0 4 0 0 0 0 0 4 0 0
Fibrotic foci Brdu+tumour 3 0 0 4 0 4 1 0 0 2 0 0
Brdu+tumour 0 19 20 0 23 19 0 9 8 0 8 9
Different numbers of PDVC57B cells (2 10
4 and 5 10
4) were implanted to create each tumour tract in the rectus and gastrocnemius muscles and the mice (n¼5) gavaged
daily with ZD4190, vehicle (V) or were untreated (C). The different patterns of tumour outgrowth were assessed by morphological examination and BrdU staining. The number
of fibrotic foci forming for each group of rodents and the pattern of Brdu expression is shown. A maximum number of five tracts were implanted into each rectus muscle and two
into the gastrocnemius. Significantly more fibrotic foci formed in the rectus muscle (P¼0.001, w
2 38) and the gastrocnemius (P¼0.001, w
2 73.7) when treatments with ZD4190


































































































































Figure 2 Treatment with ZD4190 reduced the area and microvascu-
larity of tumour foci in a muscle model of minimal residual carcinoma.
ZD4190 reduced (A) the tumour area at day 22 when more than
10
5 PDVC57B cells were implanted to create each tract in the rectus and
gastrocnemius muscles for groups of mice (n¼5) and (B) the MVD
of the tracts that developed in the gastrocnemius at day 9 and at both sites
at day 22.
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Translational research, based on the application of molecular
diagnostics to detect residual tumour after surgery for head and
neck carcinoma, has highlighted the need to identify treatment
modalities, other than radiotherapy, to prevent recurrence at the
operative site (Huang et al, 2007). Vascular endothelial cell growth
factor signalling inhibitors are attractive for the treatment of
residual disease, as tumour regrowth is dependent on neovascu-
larisation, and in this report, we show that ZD4190 can prevent
outgrowth of malignant cells when the tumour burden is below a
critical threshold.
We developed preclinical models implanting varying numbers
of malignant cells to mimic the clinical situation where residual
carcinoma interacts with the surrounding host cells and matrix to
obtain nutrients and subsequently to develop an independent
vasculature. Different numbers of cells were implanted so that the
effect of ZD4190 could be tested against different tumour burdens.
We identified 2 10
4 cells per tract as the lowest number that
reproducibly generated viable tumour tracts and implanted a
maximum of 2.5 10
6 cells when considering the treatment effect
with a higher tumour burden. The onset of endothelial cell
proliferation was established by dual immunostaining as reagents
that differentiate between new and established tumour vessels,
for example the murine homologues of magic roundabout
(Huminiecki et al, 2002) or tumour endothelial cell markers
(Nanda et al, 2004a,b), are not yet available. Proliferating
endothelial cells were detected at the tumour periphery at day 8
and at the centre from day 12. However, double-stained cells were
difficult to detect and our step-serial approach must have missed
these events, at least in the rectus, as the MVD for this muscle was
greater than that for the gastrocnemius at day 9.
We anticipated that implanting different numbers of PDVC57B
cells would result in differences in the area of the tumour tracts at
the early time point, but no such relationship was found. However,
when five tracts, each with 1 10
5 cells, were implanted into the
rectus, the MVD was consistently higher than that when two tracts
(2 10
5 cells in total) were introduced into the gastrocnemius. The
different microvessel densities are explained on the basis that
MVD reflects the balance of pro- and antiangiogenic stimulators in
the tissue environment and is not only a measure of the metabolic
burden or the angiogenic dependence of the supported tumour
cells (Hlatky et al, 2002). The higher MVD score for the
carcinomas developing in the rectus indicates that implanting
more malignant cells into this muscle provides a greater
angiogenic signal than that when fewer cells are implanted into
the gastrocnemius. However, any new vessels are unlikely to be
functional at day 9, as the tumour area is similar for both muscles,
indicating that proliferation is limited by the available nutrients.
We started treatment immediately after tumour cell implantation,
because when treating patients it makes sense to give adjuvants
early, as the growth of residual malignant cells may be stimulated
when the wound bed contains many growth factors. We showed that
following implantation of small numbers of malignant cells (a
maximum of 5 10
4 cells per tract), ZD4190 has the potential to
prevent tumour outgrowth. The most frequent findings were fibrotic
foci that represent a spectrum of change as hypoxic malignant cells
die elicit an inflammatory response, phagocytes clear debris and
granulation tissue is remodelled. Typically, these were associated
with vascular hot spots and this enhanced blood supply may help
recruit scavengers that clear any debris.
We did not detect endothelial cell proliferation until day 8, yet
when the tumour burden was low (2–5 10
4 cells implanted to
create each tract), ZD4190 prevented outgrowth of most of the
implanted cells. This suggests that this agent exerts its effects by
blocking vasodilatation and the changes in permeability that aid
the process of vessel co-option and increase diffusion of nutrients
to the tumour, as well as by modulating endothelial cell
proliferation. Dynamic contrast-enhanced magnetic resonance
imaging of vascular changes induced by ZD4190 has shown that
this agent reduces vessel permeability and modulates blood flow
(Checkley et al, 2003). An alternative explanation for these
findings is that ZD4190 inhibits EGFR signalling, but this receptor
is not highly expressed on PDVC57B cells and the drug had no
cytotoxic effect in vitro, supporting the notion that the primary
action is to inhibit angiogenesis mediated by VEGFR2. Some
tumour nodules that developed in the ZD4190-treated rodents
contained viable malignant cells. Most likely, these did not
proliferate as they were too far from blood vessels to obtain
adequate nutrients by diffusion. A small number of fibrotic foci
also contained proliferating tumour cells, suggesting that they are
able to overcome the effects of the drug, or become vascularised by
pathways that do not involve VEGFR2.
The treatment effects were different when more than 10
5 cells
were implanted to create each tract. At day 9, the tumour area in
the rectus and gastrocnemius muscles was broadly similar for the
test and the control groups, although there was a reduction in
the MVD of the fibrotic foci in the gastrocnemius. Most likely, the
reduction in MVD is confined to tumours in the gastrocnemius as
the tumour burden is less and the drug blocks any proangiogenic
stimuli. However, this response does not translate into a reduction
of tumour area for either muscle at this time, presumably as
proliferation of the implanted cells is not critically dependent on
the presence of functional new vessels.
When treatment with ZD4190 was continued for 22 days, there
was a significant reduction in the tumour area, in the micro-
vascularity and increased necrosis when the test and vehicle-
treated groups were compared. This illustrates that as the tumour
expands it becomes critically dependent on new vessel formation
and the drug modulates the balance of pro- and inhibitory
angiogenic factors, mirroring the earlier experience indicating that
antiangiogenic agents are more effective when given over a longer
term (Ciardiello et al, 2003). The difference in the morphology of
the ZD4190-treated tumours, with areas of peripheral necrosis,
cord-like proliferation of malignant cells and reduced micro-
vascularity can all be attributed to inhibition of VEGFR2
signalling. The infiltrative growth pattern suggests that this change
is driven by hypoxia as a consequence of the reduced tissue
vascularity. However, blockade of the VEGF pathway is too narrow
an approach to prevent outgrowth of residual carcinoma when
more than a critical tumour burden is present, as the drug effect is
overwhelmed by proangiogenic signals and the tumour may use
other compensatory angiogenic pathways.
ZD4190 was replaced by ZD6474 in development, as this agent
has better bioavailability (Wedge et al, 2002). These agents are
highly insoluble and could not be delivered locally, but they can be
given orally, and as dosing does not require hospital supervision,
patient acceptance is likely to be very good. These antiangiogenic
drugs can also be combined successfully with other modalities,
including radiotherapy (Williams et al, 2004), and we anticipate
that blocking multiple targets will come to the fore as the need to
provide additional treatment for cases at high risk of local
recurrence is recognised. On the basis of the results from this
study, it may be inferred that additional treatments should
commence as soon after surgery as feasible, as all agents will be
most effective when the tumour burden is low. ZD6474 is in phase
I clinical trial for unresected stage 3–4 head and neck squamous
cell carcinoma in combination with radiation, or with cisplatin and
radiation therapy, and should be considered for inclusion in
adjuvant treatment regimes for cases with microscopic or
molecular evidence of residual carcinoma.
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